Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Part of paid clinical trials in Duarte, California.

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT00004889
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
    375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.

Study Details

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have Waldenstrom's macroglobulinemia.

Key Dates

Start date
Dec 31, 1999
Status verified
Jul 2012
Primary completion
Jan 31, 2002
Completion
Jul 31, 2005

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rituxan
    375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.

Primary Outcome Measure

Response (delay in disease progression or timing of disease progression) [ Time Frame: 24 weeks ]

Locations (7)

FacilityCityStateZIPSite coordinators
Cancer Center and Beckman Research Institute, City of HopeDuarteCalifornia91010-3000-
Jonsson Comprehensive Cancer Center, UCLALos AngelesCalifornia90095-1781-
Walter Reed Army Medical CenterWashington D.C.District of Columbia20307-5000-
Brigham and Women's HospitalBostonMassachusetts02115-
Dana-Farber Cancer InstituteBostonMassachusetts02115-
Massachusetts General Hospital Cancer CenterBostonMassachusetts02114-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10021-

Find similar trials in Duarte, CA

By research site
Cancer Center and Beckman Research Institute, City of Hope· Duarte, CAJonsson Comprehensive Cancer Center, UCLA· Los Angeles, CAWalter Reed Army Medical Center· Washington D.C., DCBrigham and Women's Hospital· Boston, MADana-Farber Cancer Institute· Boston, MAMassachusetts General Hospital Cancer Center· Boston, MA

Related Studies